{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:19:16Z","timestamp":1783570756914,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This work was supported by Sotio Biotech a.s."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16185-x","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:15:46Z","timestamp":1779336946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOT102, a novel CLDN18.2-targeting antibody-drug conjugate, exhibits strong therapeutic potential in solid tumors"],"prefix":"10.1186","volume":"26","author":[{"given":"Iva","family":"Valentov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka Kyrych","family":"Sad\u00edlkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Bammert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Waldmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Beerli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Proch\u00e1zkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Jab\u016frek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Spitzov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli\u0161ka","family":"Kohelov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"R\u00e4s\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Moebius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"\u0160p\u00ed\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"2","key":"16185_CR1","first-page":"87","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"issue":"9742","key":"16185_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"key":"16185_CR3","doi-asserted-by":"publisher","first-page":"175883591985999","DOI":"10.1177\/1758835919859990","volume":"11","author":"WL Chan","year":"2019","unstructured":"Chan WL, et al. Third-line systemic treatment in advanced\/metastatic gastric cancer: a comprehensive review. Ther Adv Med Oncol. 2019;11:1758835919859990.","journal-title":"Ther Adv Med Oncol"},{"key":"16185_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.01.031","volume":"504","author":"DR Principe","year":"2021","unstructured":"Principe DR, et al. Trials and tribulations of pancreatic cancer immunotherapy. Cancer Lett. 2021;504:1\u201314.","journal-title":"Cancer Lett"},{"issue":"1","key":"16185_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","volume":"10","author":"P Singh","year":"2017","unstructured":"Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol. 2017;10(1):105.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"16185_CR6","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341.","journal-title":"Nat Med"},{"issue":"10389","key":"16185_CR7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368.","journal-title":"Lancet"},{"issue":"12","key":"16185_CR8","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.21873\/anticanres.13919","volume":"39","author":"JH Baek","year":"2019","unstructured":"Baek JH, et al. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer. Anticancer Res. 2019;39(12):6973\u20139.","journal-title":"Anticancer Res"},{"key":"16185_CR9","doi-asserted-by":"crossref","unstructured":"Gaspar M et al. An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. J Immunother Cancer. 2025;13(8):e011857.","DOI":"10.1136\/jitc-2025-011857"},{"key":"16185_CR10","doi-asserted-by":"publisher","first-page":"118863","DOI":"10.1016\/j.biopha.2025.118863","volume":"193","author":"G Calice","year":"2025","unstructured":"Calice G, Calabrese C, Notarangelo T. Innovative CAR-T approaches targeting Claudin 18.2 to counteract drug resistance in gastric cancer. Biomed Pharmacother. 2025;193:118863.","journal-title":"Biomed Pharmacother"},{"key":"16185_CR11","doi-asserted-by":"crossref","unstructured":"Dominguez Wiscovitch A, Sanchez Mendez RJ, Chuy J. CLDN18.2-targeted therapy in gastrointestinal cancers. Cancers (Basel). 2025;17(23):3764.","DOI":"10.3390\/cancers17233764"},{"issue":"21","key":"16185_CR12","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","volume":"21","author":"T Niimi","year":"2001","unstructured":"Niimi T, et al. claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol. 2001;21(21):7380\u201390.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"16185_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","volume":"481","author":"O Tureci","year":"2011","unstructured":"Tureci O, et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene. 2011;481(2):83\u201392.","journal-title":"Gene"},{"issue":"23","key":"16185_CR14","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624\u201334.","journal-title":"Clin Cancer Res"},{"key":"16185_CR15","doi-asserted-by":"publisher","first-page":"1132319","DOI":"10.3389\/fonc.2023.1132319","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen J, et al. Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications. Front Oncol. 2023;13:1132319.","journal-title":"Front Oncol"},{"issue":"3","key":"16185_CR16","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ijc.28400","volume":"134","author":"S Woll","year":"2014","unstructured":"Woll S, et al. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014;134(3):731\u20139.","journal-title":"Int J Cancer"},{"issue":"1","key":"16185_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12885-023-10533-x","volume":"23","author":"F Wang","year":"2023","unstructured":"Wang F, et al. Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours. BMC Cancer. 2023;23(1):44.","journal-title":"BMC Cancer"},{"issue":"9","key":"16185_CR18","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/ijc.28857","volume":"135","author":"P Micke","year":"2014","unstructured":"Micke P, et al. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer. 2014;135(9):2206\u201314.","journal-title":"Int J Cancer"},{"issue":"6","key":"16185_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327\u201344.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"16185_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, et al. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18(1):51.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"16185_CR21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1080\/19420862.2016.1160990","volume":"8","author":"L Waldmeier","year":"2016","unstructured":"Waldmeier L, et al. Transpo-mAb display: Transposition-mediated B cell display and functional screening of full-length IgG antibody libraries. MAbs. 2016;8(4):726\u201340.","journal-title":"MAbs"},{"issue":"5","key":"16185_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1158\/1535-7163.MCT-16-0688","volume":"16","author":"N Stefan","year":"2017","unstructured":"Stefan N, et al. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. Mol Cancer Ther. 2017;16(5):879\u201392.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"16185_CR23","doi-asserted-by":"publisher","first-page":"e0131177","DOI":"10.1371\/journal.pone.0131177","volume":"10","author":"RR Beerli","year":"2015","unstructured":"Beerli RR, et al. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. PLoS ONE. 2015;10(7):e0131177.","journal-title":"PLoS ONE"},{"issue":"10","key":"16185_CR24","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/1535-7163.MCT-23-0164","volume":"22","author":"C Kong","year":"2023","unstructured":"Kong C, et al. MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. Mol Cancer Ther. 2023;22(10):1128\u201343.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"16185_CR25","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","volume":"19","author":"JA Scribner","year":"2020","unstructured":"Scribner JA, et al. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer. Mol Cancer Ther. 2020;19(11):2235\u201344.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"16185_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","volume":"7","author":"L D\u2019Amico","year":"2019","unstructured":"D\u2019Amico L, et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer. 2019;7(1):16.","journal-title":"J Immunother Cancer"},{"issue":"Supplement 16","key":"16185_CR27","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1200\/JCO.2023.41.16_suppl.3082","volume":"41","author":"GH Konecny","year":"2023","unstructured":"Konecny GH, Winterhoff A, Chander BJ, Bilic C, Davenport S, Chung S, Miller A, Press L-L, Letrent M, Slamon S. Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors. J Clin Oncol. 2023;41(Supplement 16):3082\u20133082.","journal-title":"J Clin Oncol"},{"key":"16185_CR28","unstructured":"Biochempeg. ADC drugs targeting Claudin18.2. 2023. Available from: https:\/\/www.biochempeg.com\/article\/345.html. Cited 18 Dec 2024."},{"issue":"2","key":"16185_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185\u2013229.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"16185_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med"},{"key":"16185_CR31","doi-asserted-by":"crossref","unstructured":"Nicolaides NC, Kline JB, Grasso L. NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16\/CA125 inhibitory effects. PLoS One. 2023;18(5):e0285161.","DOI":"10.1371\/journal.pone.0285161"},{"issue":"12","key":"16185_CR32","doi-asserted-by":"publisher","first-page":"e0260954","DOI":"10.1371\/journal.pone.0260954","volume":"16","author":"I Wilkinson","year":"2021","unstructured":"Wilkinson I, et al. Fc-engineered antibodies with immune effector functions completely abolished. PLoS ONE. 2021;16(12):e0260954.","journal-title":"PLoS ONE"},{"issue":"10","key":"16185_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/protein\/gzw040","volume":"29","author":"T Schlothauer","year":"2016","unstructured":"Schlothauer T, et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016;29(10):457\u201366.","journal-title":"Protein Eng Des Sel"},{"key":"16185_CR34","doi-asserted-by":"publisher","first-page":"919819","DOI":"10.3389\/fphar.2022.919819","volume":"13","author":"Z Qiu","year":"2022","unstructured":"Qiu Z, et al. The Role and Therapeutic Potential of Macropinocytosis in Cancer. Front Pharmacol. 2022;13:919819.","journal-title":"Front Pharmacol"},{"key":"16185_CR35","doi-asserted-by":"crossref","unstructured":"Sheyi R, de la Torre BG, Albericio F. Linkers: an assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics. 2022;14(2):396.","DOI":"10.3390\/pharmaceutics14020396"},{"issue":"1","key":"16185_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12876-023-02924-y","volume":"23","author":"C Wang","year":"2023","unstructured":"Wang C, et al. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. BMC Gastroenterol. 2023;23(1):283.","journal-title":"BMC Gastroenterol"},{"issue":"20","key":"16185_CR37","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett KJ, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063\u201370.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"16185_CR38","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.yrtph.2015.01.014","volume":"71","author":"H Saber","year":"2015","unstructured":"Saber H, Leighton JK. An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol. 2015;71(3):444\u201352.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"5","key":"16185_CR39","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.21037\/tcr-19-1876","volume":"9","author":"JY Hong","year":"2020","unstructured":"Hong JY, et al. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Transl Cancer Res. 2020;9(5):3367\u201374.","journal-title":"Transl Cancer Res"},{"key":"16185_CR40","unstructured":"FDA. FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma?utm_medium=email&utm_source=govdelivery"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16185-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16185-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16185-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:12:12Z","timestamp":1783570332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16185-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16185"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16185-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gender-pooled human K3EDTA plasma (Catalog No. HUMANPLK3-0103451, Lot HMN1362972; BioIVT) was used in this study. Plasma was obtained under an Institutional Review Board (IRB)-approved protocol (WCG IRB, Protocol No. 2010-017, IRB Tracking No. 20161665), with prospective collection of biological specimens from consenting donors for research purposes. All procedures complied with ethical guidelines for human subject research.All animal studies were conducted under institutional and national regulations for the care and use of laboratory animals. PDX and CDX studies were approved by Charles River Laboratories (Regierungspr\u00e4sidium Freiburg) and Biocytogen IACUC (Beijing). Cynomolgus monkey toxicity studies were performed in an AAALAC-accredited, GLP-compliant facility, in accordance with EU Directive 2010\/63\/EU and French decree No. 2013-118, and authorized under APAFIS #2015122215443923. All procedures adhered to ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors IV, LKS, IP, FJ, TS, EK, KR, UM, RS were employed by SOTIO Biotech a.s. Authors LB, LW, RB were employed by NBE-Therapeutics AG. Authors IV, LKS, UM, LB, LW and RB are inventors of the patent covering the Claudin 18.2 antibody-drug conjugate which is described in the manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"829"}}